FDA Giving King's CorVue A Chance Despite Failed Trials
This article was originally published in The Pink Sheet Daily
Cardio-renal advisory committee will review King's CorVue efficacy data from studies that departed from FDA's development guidance.
You may also be interested in...
Despite voting that King's CorVu is not equivalent to its study comparator, Cardio-Renal panel sees bright future for the stress agent.
Drug manufacturers made a pledge to contribute $80 bil. in a mix of savings and revenue-raising initiatives to help fund health reform. In return, they could see a wide range of new business depending on how you look at the numbers.